Lixisenatide · source year
4 selected, source-linked Lixisenatide records carrying a 2024 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
4 selected records.
3 represented types.
4 distinct public records.
Cited chronology
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02049034 at 2026-07-30T18:37:14.684Z. Its registry update date was 2024-12-16, and PeptideScanner's reviewed identity mapping was lixisenatide.
Source: ClinicalTrials.gov ↗
Regulatory
DailyMed lists Structured Product Labeling version 19 for the reviewed Lixisenatide label family with a published date of 2024-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PubMed lists PMID 38949062 in Biomacromolecules as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2024-07-01 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗
Literature metadata
PubMed lists PMID 28179743 in Hospital pharmacy as Journal Article, with publication-date metadata of 2017-01 (month precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
Source: PubMed ↗